Complete radiologic and molecular response of HIV-negative primary effusion lymphoma with short-course lenalidomide

Ann Hematol. 2017 Jul;96(7):1211-1213. doi: 10.1007/s00277-017-2995-9. Epub 2017 Apr 22.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged, 80 and over
  • DNA, Viral / blood
  • Drug Eruptions / etiology
  • Drug Eruptions / prevention & control
  • Drug Monitoring
  • Eosinophilia / chemically induced
  • Eosinophilia / prevention & control
  • Epstein-Barr Virus Infections / blood
  • Epstein-Barr Virus Infections / drug therapy
  • Epstein-Barr Virus Infections / immunology
  • Epstein-Barr Virus Infections / virology
  • Gastrointestinal Stromal Tumors / diagnostic imaging
  • Gastrointestinal Stromal Tumors / drug therapy
  • Gastrointestinal Stromal Tumors / immunology
  • Gastrointestinal Stromal Tumors / pathology
  • Herpesvirus 4, Human / drug effects
  • Herpesvirus 4, Human / immunology
  • Herpesvirus 4, Human / isolation & purification
  • Herpesvirus 4, Human / metabolism
  • Humans
  • Immunologic Factors / adverse effects
  • Immunologic Factors / therapeutic use*
  • Lenalidomide / adverse effects
  • Lenalidomide / therapeutic use*
  • Lymphoma, Primary Effusion / diagnostic imaging
  • Lymphoma, Primary Effusion / drug therapy*
  • Lymphoma, Primary Effusion / immunology
  • Lymphoma, Primary Effusion / virology
  • Male
  • Neoplasm Recurrence, Local / diagnostic imaging
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / immunology
  • Neoplasm Recurrence, Local / pathology
  • Neoplasms, Second Primary / diagnostic imaging
  • Neoplasms, Second Primary / drug therapy*
  • Neoplasms, Second Primary / immunology
  • Neoplasms, Second Primary / virology
  • Radiography, Thoracic
  • Treatment Outcome
  • Tumor Burden / drug effects

Substances

  • DNA, Viral
  • Immunologic Factors
  • Lenalidomide